comparison of two brands of methylphenidate (stimdate® vs. ritalin®) in children and adolescents with attention deficit hyperactivity disorder: a double-blind, randomized clinical trial

ôbjective: to compare the effectiveness and safety of the methylphenidate produced in ïran (stimdate®) with its original brand (ritalin®) in children with âttention deficit hyperactivity disorder (âdhd). methods: ïn this double-blinded randomized clinical trial, 30 patients with âdhd who were 6 to 16 years old, were divided into two groups: 15 in stimdate® and 15 in ritalin® group. the two groups were compared for side effects profile, çonner’s parent’s rating scale-persion version (çprs-r), çhild symptom ïnventory-4 (çsï-4), çlinical global ïmpressions (çgï), and çhildren’s global âssessment scale (çgâs), at baseline and at the 4th and 6th weeks. results: the subjects showed significant decreases in the çprs-rand çsï-4 scores and significant increase of çgâs scores during the follow-up, but there were no significant difference between stimdate® and ritalin® group, regarding the pattern of changes observed. the mean therapeutic dose and the number of side effects were not significantly different between the two studied groups. çonclusions: both stimdate® and ritalin® had comparable clinical efficacy and safety in children with âdhd.